We show that IL-36R is expressed by T (CD4+ and CD8+) and B (CD19+) lymphocytes in human blood and also by CD4+ T lymphocytes in the intestinal lamina propria. IL-36R protein was mostly stored in the cytoplasm of CD4 lymphocytes and B cells, during steady andthe greatest expression of IL-36R mRNA was measured in CD4+ (T helper) lymphocytesIL-36 β, which functions via IL-36R induced rapid and significant (P <0.05) proliferation of CD4+ lymphocytes, within 48h. IL-36R expression was also maintained on the surface of circulating CD4+ lymphocytes which enter the intestinal lamina propria.
Cell isolation and culture

Isolation of peripheral blood lymphocytes and cell sorting
Blood products from healthy donors were obtained from the National blood transfusion service (Sheffield, UK). Isolation of peripheral blood mononuclear cells (PBMC) was performed using differential centrifugation in histopaque 1077 (Sigma-Aldirich, UK) by standard methods. The isolated PBMC were incubated with magnetic microbeads conjugated with mouse anti-human CD19 + , anti-human CD4 + , CD3 + or anti-human CD8 + antibodies (Miltenyi Biotec, Bisley, UK) for 20 min at 6ºC.
The labeled cells were separated by passing the cell suspension over a magneticactivated cell sorter (AutoMACS, Miltenyi Biotec, Germany). Each population was carefully removed from the columns and were separately kept in culture in RPMI 1640 media supplemented with 10% (v/v) Fetal Calf Serum, 200mM L-glutamine and 5 mL of antibiotic solution containing 100 IU of penicillin and 1mg of streptomycin per mL (Sigma-Aldirich, UK).
Isolation of human ileal lamina propria cells
Fresh, histologically normal mucosal samples, surplus to clinical requirements, were obtained from human terminal ileum resected (as part of right hemicolectomy specimens) for tumour. Ethical committee approval was provided by the Nottingham Research Ethics Committee. Mucosal samples were obtained at least 5 cm from the tumour. The mucosal samples were washed thoroughly with calcium-and magnesium-free Hanks balances salt solution (HBSS; Gibco BRL, Gaithesburg, MD, USA), to remove adherent luminal material. Lamina propria cells were isolated from mucosal samples using a previously described technique [9] . 6 Briefly, dissected strips of mucosa were weighed and incubated in 1 mmol/l dithiothreitol solution (DTT) (Sigma, Poole, Dorset, UK) for 20 minutes at room temperature. To remove the epithelial cells, mucosal strips were treated three times with 1 mmol/l ethylenediamine tetra-acetic acid (BDH, Poole, Dorset, UK) at 37°C for 30 min. Between each incubation step the strips were washed with calcium and magnesium-free HBSS.
The mucosal samples, denuded of epithelial cells, were subsequently cultured at 37 0 C in RPMI containing 10% fetal calf serum (Gibco) in 60 mm tissue culture dishes (Costar Corp, Cambridge, MA, USA). During culture, cells appeared both in suspension and attached to the tissue culture dishes. After a 24h culture period, these cells were collected by transferring the pieces of mucosal tissue to culture dishes containing fresh media and incubating the original dishes (containing cells only) at 4 0 C for 60 min. Following pippeting to detach adherent cell, the cells were counted and viability tested using Trypan blue (4 μg/ml) and were found to be between 90-
100% viable.
Depending on down-stream applications, the isolated lamina propria cells were suspended in appropriate medium at a density of 1x10 6 cells/ml. To stabilize RNA prior to extraction, samples for qRT-PCR analysis were immediately pelleted and suspended in RNAlater RNA Stabilization Reagent according to the Manufacturer's recommendations (QIAGEN, Crawley UK). Total RNA was extracted from the cells, reverse-transcribed into cDNA and amplified in a typical real time PCR reaction. A relative quantification analysis using GAPDH as the reference gene and IL-36R as the target gene was performed on a LightCycler® 480 analyser. HT 29 cells and THP-1 cells were used as positive and negative controls respectively. FACS analyses were also performed on migrated cells to ascertain overall CD3+ population, CD4+ 7 population within the CD3+ populations and expression of IL-36R protein by CD4+ cells. Each analysis was performed in triplicate on 5 separate occasions.
HT 29 cell cultures
The human colonic epithelial carcinoma cell line, HT-29 (was a kind gift from Professor Susan Watson, University of Nottingham) was used as a positive control for IL-36R expression, as previously reported [10] Cells were cultured in Dulbecco's modified Eagle's medium supplemented with glucose (25mM), Sodium Bicarbonate (44mM), Transferrin (10mg/l), sodium pyruvate (1mM), L-glutamine (2mM), 0.1 mM non-essential amino acids (NEAA) and 10% FCS. Cell cultures were maintained in humidified incubators at 37°C, 5% CO2. The medium was changed every day to prevent glucose exhaustion.
Flow Cytometry
Following cell sorting, FACS analyses were performed by standard methods. Briefly, 1×10 6 test cells of each purified cell population (CD19 + , CD4 + and CD8 + ) were resuspended in FACS buffer (BSA 1% w/v); EDTA (2 mM). The cells were blocked in FACS buffer containing human serum (10% v/v) for 15 min and some cell preparations were permeabilized with 10% (w/v) Saponin (Sigma-Aldirich, UK).
Permeabilized and non-permeabilized cells were incubated for 45min with mouse anti-human IL-36R antibody (Amgen, USA) or with IgG2a isotype control conjugated with FITC for negative controls (Abcam, UK). Cells were then analysed using an FACSCanto II analyser (Becton Dickinson, USA). Samples were acquired using the CellQuest pro software (Becton Dickinson) and analysed using the WinMDI 2.8 software. Cell viability was assessed by propidium iodide uptake (20 µg/mL for 10 min) via FACS analysis and was found to be >90% in all cases. [11] . THP-1 cells were used as a negative control and HT29 cells were used as positive controls for IL-36R expression. Primer 9 sequences are shown in table 1and as previously reported [12] [13] and PCR product obtained was also shown to be of correct size as that previously reported [12] .
Analysis of IL-36R protein expression by immunocytochemistry
An aliquot of approximately 10 3 purified CD4 + , CD8 + and CD19 + cells was separately collected from cell culture, washed in 1mL of PBS and centrifuged at 250 g for 5 min.
Cells were suspended in 500µL of PBS and centrifuged at 800rpm in the CytoSpin 4 (ThermoScientific, UK) to lay the cells in the slides. Initially the cells were fixed on ice cold solution of acetone and methanol 1:1 (v/v) for 2 min and the slides were was compared with negative control cells, incubated without the primary antibody.
Lymphocyte proliferation assays
A standard WST-1 cell proliferation assay (Roche Diagnostics Ltd., West Sussex, UK) was used (as per manufacturer's instructions) to measure proliferation of lymphocytes (10 4 cells/100μl RPMI medium) after 48h culture in IL-36β (100 ng/ml). We deliberately used a very short culture period to ascertain true proliferation rather than increased survival which was shown to be problematic in other studies. Results from the colourimetric assay were compared by measuring absorbance at 450 nm on a Labtech LT-4000 ELISA Plate Reader and to assess mitochondrial enzyme activity, these were compared to a standard curve obtained from control lymphocytes. Lymphocytes cultured with Concanavalin A (conA) (75μg/ml) over the same time period were used as a positive control while unstimulated lymphocytes were used as a negative control.
Statistical Analysis
An ANOVA test with a one way classification was used to determine significant differences, at the 95% confident interval, in the numbers of lymphocytes which had divided after 24h. A post-hoc test (Tukey's) was then used to identify means which were significant. Statistical data was analysed using SPSS software, licenced to the University of Nottingham.
Results
Initially we investigated IL-36R expression in non-adherent cells in blood buffy coats and found this to be positive (above that expressed by the positive control, HT-29 cells). We then found that most of the IL-36R signal was coming from the CD3+ (pan T cell) fraction (Fig 1) . When we examined IL-36R expression in the granulocyte fraction (below the buffy coat) we found that these cells did not express the receptor and was comparable to the negative control cell line (THP1) (Fig 1) . The next set of experiments investigated IL-36R mRNA expression in blood lymphocyte subsets compared with HT29 cells (positive control). Quantitative PCR analysis showed that in all lymphocyte subsets, constitutive IL-36R mRNA expression was greater than that measured in HT29 cells but this increase was significant (P <0.05) only in CD4+ T cells (Fig 2A) . We then incubated CD4+ lymphocytes with varying concentrations of IL-36β, to ascertain whether this would alter IL-36R expression relative to constitutive levels. Our results showed that all concentrations of cytokine (10-500 ng/ml) significantly increased IL-36R expression above constitutive levels but this was greatest at 100-200 ng, at which there was a plateau in IL-36R mRNA expression ( Fig 2B) .
We then used fluorescent microscopy to investigate the cellular distribution of IL-36R in lymphocytes. IL-36R immunoreactivity was detected on the cell membranes of CD4+ and CD8+ T lymphocytes as well CD19+ B lymphocytes (Fig 3) . In all cases the immunoreactivity was comparable to that observed in HT29 cells (Fig 3 panel B) which have previously been used as an IL-36R positive control. In contrast, a negative control panel (without IL-36R antibody and secondary antibody only) showed no nonspecific binding to these cells (control overlay D). However, this study also showed what appeared to be cytoplasmic localisation of IL-36R in both CD4+ and CD19+ lymphocytes, as well as HT29 cells but this was much less clear in CD8+ lymphocytes (Fig 3 panel B) . To further investigate both expression and localisation of IL-36R protein, we used FACS analysis on non-permeabilised (cell membrane only) and permeabilised (cell membrane and cytoplasm) cells. Our results show that most of the measured IL-36R protein in CD4+ cells was within the cell cytoplasm with an associated increased shift in IL-36R compared with non-permeabilised cells ( Fig 4A) . In contrast to CD4+ lymphocytes, the levels of IL-36R protein detected in CD8+ lymphocytes was comparable in both permeabiled and non-permeabiled cells, implying that most expression was membrane associated ( Fig 4B) . In both CD19+ B lymphocytes ( Fig 4C) and in HT29 cells ( Fig 4D) IL-36R protein expression was increased in permeabilised cells but the associated shifts between IL-36R protein expression in permeabilised and non-permeabilised cells was not as large as that measured in CD4+ lymphocytes. To investigate whether ligation of IL-36R had any physiological effect on CD4+ lymphocytes, we measured lymphocyte proliferation after culturing the cells with IL-36β for 48h. Our studies showed that CD8+ T lymphocytes and CD19+ B lymphocytes did increase in number in cultures exposed to IL-36β but this change was not statistically significant. However, IL-36β did induce CD4+ T lymphocytes to proliferate at significantly higher (P < 0.05) numbers than unstimulated controls ( Fig 5) . In all cases, proliferation was low, probably due to the short culture period used.
The dynamic circulation of immune cells from blood into tissues can have profound effects on the expression of numerous proteins. With this in mind, we then investigated whether expression of IL-36R was maintained, lost or reduced when CD4+ lymphocytes enter peripheral tissues. We chose surgically resected (normal) human intestinal mucosal tissues for this analysis. Initially (following cellular isolation from the lamina propria; LP) we measured the population of CD3+ (pan T cells) lymphocytes and within this population the number of CD4+ cells, to ascertain whether CD4+ cells were a good representative population to study (i.e in sufficient numbers within the tissues. Our results show that 75% of cells which migrated from the LP tissues were CD3+ (Fig 6A & B) and of these, 55% were CD4+ (Fig 6C & D) .
We then measured IL-36R mRNA expression in isolated intestinal LP cells by qPCR
and compared this to expression by HT29 cells (positive control) and THP1 monocytes (negative control). This showed that LP cells expressed IL-36R at higher levels than HT29 cells ( Fig 7A) and when we further analysed the CD4+ subpopulation within the total isolated LP population (by FACS analysis) we found that they expressed IL-36R on their cell membranes ( Fig 7B) .
Discussion
The study we report is the first to show that human blood lymphocytes express the novel IL-1 family cytokine receptor IL-36R. The study therefore shows differences in the expression of IL-36R between humans and mice. In mice IL-36R has been reported to be expressed by splenic CD4+ T lymphocytes but not by CD8+ T lymphocytes or B lymphocytes [2] . Our study also differs from that of Foster et al., [14] which reports a lack of expression of IL-36R in human lymphocytes. It is possible that that some anomalies have arisen due to differences in this study and ours.
We have used three different methods to show expression of IL-36R mRNA and protein in human Th cells, CTLs and B lymphocytes. In our studies all reagents were LPS tested and the IL-36R antibody used was monoclonal, unlike the polyclonal antibody used in the aforementioned study. We also used the same PCR probe we successfully reported on before [12] [13] and visualised the PCR product, using an agarose gel, which was found to be the correct size for IL-36R (data not shown). Our data shows differences in the expression pattern of IL-36R in different lymphocytes, with CD4+ lymphocytes (and to a lesser extent B lymphocytes) containing large cytoplasmic stores of the receptor, whereas in CD8+ lymphocytes most of the IL-36R protein is found on the cell membrane. We then studied whether, or not, IL-36 β altered expression of IL-36R in CD4+ lymphocytes and found that IL-36R expression plateaued when the cells were incubated with 100-200 ng/ml IL-36β. Human IL-36αγ have been shown before to be effective at relatively low doses, when compared to murine homologues [12] [13] . The current study is, therefore, consistent with the latter since culture of CD4+ cells with IL-1β at 500 ng/ml decreased IL-36R expression, when compared to expression at 100-200 ng/ml, which also indicates a negative feedback loop shown in a previous paper [12] .
Classic IL-1 cytokines are known to indirectly induce T cell proliferation by enhancing APC maturation and survival [15] [16] and we have recently shown that this is also the case for IL-36β and IL-36γ-stimulated human monocyte derived dendritic cells (MDDCs) [12] . Few studies have reported the direct effect of classic IL-1 cytokines on lymphocyte proliferation. However, Ben-Sasson et al., [17] have shown that antigen-primed murine CD4+, Th cells proliferate in response to IL-1β. In this study, CFSE analysis showed that IL-1β stimulation was responsible for only about a 2 fold increase in CD4+ Th cells and that the overall 7-8 fold increase measured at the end of the experiments was mostly due to enhanced survival of IL-1β-stimulated Th cells. Similarly, IL-1β has also been shown to induce the proliferation of human IL-17 producing, CD4+ Th cells [18] and IL-17/Th memory cell populations [19] . Due to measuring proliferation after only 48h, our studies show that there is a rapid effect of IL-36β which cannot be due merely to increased survival as has been shown in some other studies mentioned above. However, the down-side to using a short incubation period was that quite low numbers of cells had proliferated and also we cannot say if CTL or B cell proliferation may have surpassed that of CD4+ lymphocytes after a longer period of time. Nevertheless the study did show some functionality of this receptor in CD4+ lymphocytes.
If expression of IL-36R by lymphocytes has some functional significance in disease within peripheral tissues, then expression of IL-36R must be maintained on the cell membrane of lymphocytes as they enter the tissues from circulation. We found that IL-36R mRNA was expressed in the lamina propria at higher levels than was expressed by HT-29 (positive) cells. Intestinal samples were then denuded of epithelium and cultured to allow migration of cells from the LP. Consistent with a previous study [9] , 75% of the cells which migrated from the LP, after 36h, were CD3+ T cells and of these 55% expressed CD4. However, we show for the first time that the CD4+ population within the LP also expressed IL-36R. Usually γδ T cells, which reside in the intestine, do not express CD4 [20] but rare γδ/CD4+ T phenotypes have been shown to be expanded in patients with rare genetic disorders such as CD3δ deficiency, a form of severe combined immunodeficiency [21] . Intra-epithelial lymphocyte populations are known to increase in patients with various intestinal disorders [22] but the model we have used denudes the intestinal epithelium which would also preclude intra-epithelial lymphocytes from the CD4/IL-36-R population we have measured. Our results, therefore, most likely indicate that CD4+ lymphocytes maintain IL-36R expression as they enter peripheral tissue from the blood. Thus, expression of IL-36R by CD4+ lymphocytes, and their activation via IL-36R cytokine ligands, could have a role in human intestinal and blood disorders.
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